(i) Discuss safety data from observational studies and a meta-analysis of RCTs since the emergence of the original signal of serious neuropsychiatric adverse events with varenicline which led to the black box warning in 2009 and; (ii) Determine whether any changes should be made to the description of this risk in varenicline's product labelling.